MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

Search

Xenon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

43.35 4.51

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

41.34

Max

44.18

Belangrijke statistieken

By Trading Economics

Inkomsten

-20M

-85M

Winstmarge

-867.293

Werknemers

316

EBITDA

-21M

-94M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+33.53% upside

Dividenden

By Dow Jones

Volgende Winsten

12 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

466M

3.1B

Vorige openingsprijs

38.84

Vorige sluitingsprijs

43.35

Nieuwssentiment

By Acuity

67%

33%

326 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 okt 2025, 23:43 UTC

Marktinformatie

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

20 okt 2025, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 okt 2025, 23:36 UTC

Marktinformatie

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

20 okt 2025, 22:14 UTC

Marktinformatie

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

20 okt 2025, 22:00 UTC

Winsten
Acquisities, Fusies, Overnames

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

20 okt 2025, 21:49 UTC

Acquisities, Fusies, Overnames

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

20 okt 2025, 20:56 UTC

Acquisities, Fusies, Overnames

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20 okt 2025, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

20 okt 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

20 okt 2025, 20:38 UTC

Winsten

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

20 okt 2025, 20:38 UTC

Winsten

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

20 okt 2025, 20:38 UTC

Winsten

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

20 okt 2025, 20:36 UTC

Winsten

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

20 okt 2025, 20:36 UTC

Winsten

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

20 okt 2025, 20:36 UTC

Winsten

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

20 okt 2025, 20:36 UTC

Winsten

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

20 okt 2025, 20:16 UTC

Marktinformatie

Canada Labor-Market Indicators Lean Dovish -- Market Talk

20 okt 2025, 20:05 UTC

Winsten

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

20 okt 2025, 19:39 UTC

Winsten
Acquisities, Fusies, Overnames

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

20 okt 2025, 19:34 UTC

Marktinformatie

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

20 okt 2025, 19:32 UTC

Marktinformatie

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

20 okt 2025, 19:00 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20 okt 2025, 18:29 UTC

Marktinformatie

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

20 okt 2025, 18:11 UTC

Marktinformatie

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

20 okt 2025, 18:04 UTC

Marktinformatie

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

20 okt 2025, 17:03 UTC

Marktinformatie

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

20 okt 2025, 17:01 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 okt 2025, 17:01 UTC

Marktinformatie

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

20 okt 2025, 16:43 UTC

Marktinformatie

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

20 okt 2025, 16:25 UTC

Marktinformatie

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

33.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 55.59 USD  33.53%

Hoogste 65 USD

Laagste 48 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

14

Buy

0

Hold

0

Sell

Technische score

By Trading Central

34.81 / 38.24Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

326 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
help-icon Live chat